{"entity":{"id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of SHR-A2102, Bevacizumab and Osimertinib in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors is a phase 2 interventional study registered as NCT06895928 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 400 participants planned, started 2025-03-28 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-A2102, Bevacizumab Injection, Adebelimab Injection, Ametinib Mesylate Tablets and Osimertinib Mesylate Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06895928","url":"https://clinicaltrials.gov/study/NCT06895928"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a2102","bevacizumab","osimertinib"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06895928","phase":"2","setting":"A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":400,"outcomes":[]},"route":"/trials/nct06895928/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}